Biocryst Pharmaceuticals (BCRX) Assets Average (2011 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Assets Average came in at $489.6 million in Q1 2026, up 0.9% YoY from $485.2 million in Q1 2025, and up 1.94% on a QoQ basis from $480.3 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Assets Average (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 16 years of Assets Average data on file, last reported at $489.6 million in Q1 2026.
- Quarterly Assets Average rose 0.9% year-over-year to $489.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $489.6 million (up 0.9% YoY) and the FY2025 annual result came in at $502.3 million, changed 0.28% from the prior year.
- Assets Average grew to $489.6 million in Q1 2026, from $480.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $557.9 million in Q1 2022 to a low of $451.8 million in Q3 2025.
- A 5-year average of $504.3 million and a median of $492.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average surged 96.88% — and 2024, when it dropped 9.55%.
- Tracing BCRX's Assets Average over 5 years: stood at $554.3 million in 2022, then dropped by 6.2% to $519.9 million in 2023, then fell by 5.6% to $490.8 million in 2024, then declined by 2.15% to $480.3 million in 2025, then increased by 1.94% to $489.6 million in 2026.
- The last three Assets Average figures came in at $489.6 million (Q1 2026), $480.3 million (Q4 2025), and $451.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 5.97 Bn |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 511.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 511.45 Mn |
| Mar 31, 2026 | 489.61 Mn |
| Dec 31, 2025 | 480.29 Mn |
| Sep 30, 2025 | 451.81 Mn |
| Jun 30, 2025 | 468.62 Mn |
| Mar 31, 2025 | 485.23 Mn |
| Dec 31, 2024 | 490.84 Mn |
| Sep 30, 2024 | 481.84 Mn |
| Jun 30, 2024 | 470.16 Mn |
| Mar 31, 2024 | 492.43 Mn |
| Dec 31, 2023 | 519.94 Mn |
| Sep 30, 2023 | 526.40 Mn |
| Jun 30, 2023 | 519.81 Mn |
| Mar 31, 2023 | 529.87 Mn |
| Dec 31, 2022 | 554.30 Mn |
| Sep 30, 2022 | 534.57 Mn |
| Jun 30, 2022 | 519.13 Mn |
| Mar 31, 2022 | 557.94 Mn |
| Dec 31, 2021 | 426.96 Mn |
| Sep 30, 2021 | 271.52 Mn |